The companies previously announced that they identified four compounds that could disrupt the function of endoribonuclease (also known as nonstructural protein-15; NSP-15). These have been synthesized and are in the process of being tested in biological assays.

Now, the companies have jointly developed a new in silico library of analog compounds, based on the main protease scaffold compound, that will be evaluated through additional in silico screening to choose which additional compounds may be synthesized and evaluated in biological assays.

Complete screening results are expected to be available within weeks.

Does SARS-CoV-2 use host defenses to infect susceptible cells?
A new study pinpoints the most likely cell types that SARS-CoV-2 infects. Unexpectedly, the study indicates that one of the body's main defenses against...

Scientists explore SARS-CoV-2 main protease as a drug target
A team of researchers report the structure of the main protease of the novel coronavirus and have identified several drugs that show promise in combating...